AUM Biosciences, Newsoara Biopharma Forge Five-Year Deal to Develop Cancer Drugs
Singapore-based drugmaker AUM Biosciences has struck a five-year deal with China’s Newsoara Biopharma to develop new cancer therapies and up to six drugs currently part of AUM’s drug pipeline.
Per the deal, AUM will receive $135 million in short-term milestone payments and will be eligible for future royalty payments in the “double digits.”
AUM said it will maintain the global rights to any new oncology treatments while Newsoara gains exclusive Chinese licensure.
AUM specializes in the development of artificial intelligence-based gene therapies for cancer.